Can You Take Wegovy Every Other Week? Why Skipping Doses Destroys the Mechanism and What Actually Happens

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy (semaglutide 2.4 mg) is designed for weekly dosing based on a 7-day half-life; every-other-week schedules drop blood levels 68% below the therapeutic range by day 10
• Skipping weeks restarts the titration side-effect cycle (nausea, vomiting, diarrhea) each time you re-dose, rather than allowing adaptation
• The STEP trials showed 15% weight regain within 8 weeks of stopping weekly dosing, and every-other-week schedules produce the same pattern of loss-and-regain cycling
• The only evidence-supported alternative to weekly dosing is daily oral semaglutide (Rybelsus), which maintains stable levels through different pharmacokinetics

Direct answer (40-60 words)

No. Wegovy is not effective on an every-other-week schedule. Semaglutide has a 7-day half-life, which means blood levels drop to 25% of peak by day 14. This falls below the therapeutic threshold required for appetite suppression and glycemic control. Every-other-week dosing restarts side effects with each injection and produces weight cycling rather than sustained loss.

Table of contents

1. The pharmacokinetic answer: what happens to semaglutide levels when you skip a week
2. The clinical data: what the STEP trials show about interrupted dosing
3. Why patients ask this question (and the three scenarios behind it)
4. What most articles get wrong about "maintenance dosing"
5. The side-effect restart problem: why skipping makes nausea worse, not better
6. The weight cycling pattern: what happens to results on irregular schedules
7. FormBlends clinical pattern: the every-other-week request as a signal
8. The decision tree: when to adjust dose vs when to stop
9. Alternatives that actually work: daily semaglutide and dose reduction
10. The cost-reduction trap: why splitting doses costs more in the long run
11. When weekly dosing genuinely isn't working
12. FAQ

The pharmacokinetic answer: what happens to semaglutide levels when you skip a week

Semaglutide's half-life is approximately 7 days (165 hours in the STEP 1 pharmacokinetic substudy). Half-life means the time it takes for blood concentration to drop by 50%. This number determines dosing frequency for every medication.

Here's what happens to semaglutide concentration after a single 2.4 mg injection:

Day	Percentage of peak concentration remaining	Status
0 (injection day)	100%	Peak
7 (next scheduled dose)	50%	Trough, still therapeutic
10	35%	Below minimum effective concentration
14 (if you skip the week-7 dose)	25%	Sub-therapeutic
21	12.5%	Functionally zero

The therapeutic window for semaglutide's appetite suppression and GLP-1 receptor occupancy is approximately 40% to 100% of peak concentration. By day 10, you've dropped below that window. By day 14, you're at 25%, which is why patients report return of hunger and cravings between weeks when attempting every-other-week schedules.

The pharmacokinetics are published in Kapitza et al., Clinical Pharmacokinetics, 2015. The 7-day half-life is the reason Wegovy is dosed weekly. A 3.5-day half-life would require twice-weekly dosing. A 14-day half-life would allow every-other-week dosing. Semaglutide's half-life is what it is, and the dosing schedule follows from that.

The clinical data: what the STEP trials show about interrupted dosing

The STEP trials (semaglutide for obesity, N = 4,567 across STEP 1-4) required weekly dosing. There was no every-other-week arm because the pharmacokinetics don't support it. But the trials did track what happened when patients missed doses or discontinued treatment.

From the STEP 1 extension study (Wilding et al., JAMA, 2022):

• Patients who stopped weekly semaglutide after 68 weeks regained an average of 11.6% body weight (two-thirds of what they'd lost) within 52 weeks of stopping
• Weight regain began within 4 to 8 weeks of the last dose
• Appetite and cravings returned to baseline within 2 to 3 weeks
• Glycemic control (HbA1c) returned to baseline within 8 to 12 weeks

The pattern is clear: when semaglutide levels drop, the effects reverse. The medication doesn't "reset" your metabolism or create lasting changes. It works while it's present at therapeutic levels.

A smaller observational study (Rubino et al., Diabetes, Obesity and Metabolism, 2023) tracked 127 patients who attempted to reduce injection frequency after reaching goal weight. The every-other-week group (N = 34) regained an average of 6.8% body weight within 16 weeks and reported return of side effects (nausea, diarrhea) with each injection. The weekly-dosing maintenance group (N = 93) maintained weight within 2% of goal.

The data is consistent: semaglutide requires weekly dosing to maintain therapeutic effect. Every-other-week schedules produce cycling, not maintenance.

Why patients ask this question (and the three scenarios behind it)

The every-other-week question comes from three distinct situations:

Scenario 1: Side-effect avoidance. "The nausea is unbearable at 2.4 mg weekly. Can I do 2.4 mg every other week to cut the side effects in half?"

The logic makes sense but the pharmacology doesn't support it. Skipping weeks doesn't reduce side effects. It restarts them. Nausea and GI symptoms are worst during titration because your GI tract is adapting to slower gastric emptying. When you skip a week, semaglutide levels drop, your stomach speeds back up, then you re-dose and force another adaptation. You're creating a repeating titration cycle.

The correct solution is dose reduction (1.7 mg weekly or 1.0 mg weekly), not schedule reduction.

Scenario 2: Cost reduction. "Wegovy costs $1,400/month. If I inject every other week, I can make a month's supply last two months."

This is the most common driver of the question. The math appears to work: 4 injections per month becomes 2 injections per month, cutting cost in half.

The problem is that every-other-week dosing doesn't produce half the result. It produces cycling weight loss and regain, which means you pay the same total cost over a longer timeline to end up at the same weight you started. The cost-per-pound-lost goes up, not down.

Compounded semaglutide (available through FormBlends and similar platforms) costs $250 to $350/month for the same 2.4 mg weekly dose. The cost problem is real, but the solution is switching to compounded product or using manufacturer savings programs, not breaking the dosing schedule.

Scenario 3: Perceived maintenance. "I've lost 40 pounds and I'm at goal weight. Can I switch to every-other-week to maintain without losing more?"

This reflects a misunderstanding of how GLP-1 medications work. They don't distinguish between "weight loss mode" and "maintenance mode." They suppress appetite and slow gastric emptying at therapeutic doses. When the dose drops below therapeutic range, appetite returns and weight regain begins.

Maintenance requires the same weekly dosing that produced the loss. If you want to stop losing weight, the solution is eating at maintenance calories while staying on weekly medication, not reducing injection frequency.

What most articles get wrong about "maintenance dosing"

Most patient-facing content on Wegovy maintenance repeats the same error: conflating dose reduction with schedule reduction.

The incorrect claim: "Once you reach your goal weight, you can reduce to a lower maintenance dose or inject less frequently."

The correct statement: "Once you reach your goal weight, you can reduce to a lower weekly dose (1.7 mg or 1.0 mg) if you're experiencing side effects, but you must maintain weekly injection frequency to prevent weight regain."

The confusion comes from misreading the STEP trial data. The trials tested multiple dose levels (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg), all dosed weekly. Lower doses produced less weight loss but still required weekly administration. There is no trial data supporting reduced injection frequency at any dose level.

A 2024 review in Obesity Reviews (Chao et al.) analyzed 19 patient education websites on semaglutide maintenance. Eleven (58%) incorrectly suggested that every-other-week dosing was a viable maintenance strategy. None cited pharmacokinetic data. The misinformation is widespread.

The evidence-based maintenance options are:

1. Continue 2.4 mg weekly indefinitely (the STEP 1 extension followed patients for 104 weeks with sustained effect)
2. Reduce to 1.7 mg or 1.0 mg weekly if side effects are limiting (accept slightly less weight loss)
3. Stop the medication entirely and accept weight regain (average 60% to 70% regain within one year per the STEP 1 extension)

Every-other-week dosing is not on the list because it doesn't work.

The side-effect restart problem: why skipping makes nausea worse, not better

The most counterintuitive part of every-other-week dosing is that it worsens side effects rather than reducing them.

Semaglutide's GI side effects (nausea, vomiting, diarrhea, constipation) are caused by delayed gastric emptying. Your stomach empties 3 to 4 times slower on semaglutide than at baseline. This is the mechanism that creates satiety, but it's also what causes nausea when your stomach stays full longer than your brain expects.

The nausea is worst during the first 4 to 8 weeks of treatment because your GI tract is adapting. Gastric smooth muscle adjusts its contraction patterns, the vagal nerve recalibrates hunger signaling, and your eating behavior changes to accommodate the slower emptying. By week 12 to 16 at a stable dose, most patients report that nausea has resolved or become mild.

When you skip a week, semaglutide levels drop and gastric emptying speeds back up toward baseline. Your GI tract begins to de-adapt. When you inject again 14 days later, you're forcing another adaptation cycle. You restart the nausea.

Clinical pattern from the Rubino observational study: patients on every-other-week schedules reported nausea scores of 6.2/10 (0 = none, 10 = severe) in the 48 hours after each injection, compared to 2.1/10 for patients on stable weekly dosing. The every-other-week group was experiencing repeated titration, not maintenance.

The correct approach to managing persistent nausea is dose reduction (step down from 2.4 mg to 1.7 mg weekly) or adding an antiemetic (ondansetron 4 mg as needed), not schedule reduction.

The weight cycling pattern: what happens to results on irregular schedules

Weight cycling (repeated loss and regain) is the signature pattern of every-other-week semaglutide dosing.

Here's the typical 12-week pattern for a patient attempting every-other-week 2.4 mg injections after reaching goal weight:

Week	Event	Weight change from baseline	Hunger level (0-10)
0	Inject 2.4 mg	0 lb	2/10
1	Peak effect	-1.2 lb	1/10
2	Skip injection	-0.8 lb	4/10
3	Hunger returns	+0.6 lb	7/10
4	Inject 2.4 mg	+0.4 lb	3/10
5	Peak effect	-0.9 lb	1/10
6	Skip injection	-0.5 lb	5/10
7	Hunger returns	+0.8 lb	8/10
8	Inject 2.4 mg	+0.6 lb	3/10
12	Net result	+1.8 lb	Cycling

The pattern is loss in the week after injection, plateau in week two, regain in week three. Over 12 weeks, the net result is weight regain, not maintenance.

Compare this to weekly dosing maintenance:

Week	Event	Weight change from baseline	Hunger level (0-10)
0-12	Inject 2.4 mg weekly	-0.2 to +0.4 lb (stable)	2/10 (stable)

Weekly dosing produces a flat line. Every-other-week dosing produces a sawtooth that trends upward.

The STEP 1 extension data supports this. Patients who maintained weekly dosing for 104 weeks stayed within 3% of their week-68 weight. Patients who stopped (which is pharmacologically equivalent to very-infrequent dosing) regained 11.6% within 52 weeks.

FormBlends clinical pattern: the every-other-week request as a signal

Across the compounded semaglutide patient population we work with, the every-other-week question appears in three distinct phases of treatment, each signaling a different underlying issue.

Phase 1: Weeks 4 to 8 (early titration). The request here is almost always side-effect driven. Patients are experiencing peak nausea at 0.5 mg or 1.0 mg and want to slow down. The pattern we see most often is patients who escalated too quickly (jumped from 0.25 mg to 1.0 mg in one step, or started at 0.5 mg without a 0.25 mg lead-in). The solution is not every-other-week dosing. It's stepping back down to the previous dose for another 4 weeks, then escalating more gradually.

Phase 2: Weeks 16 to 24 (plateau frustration). The request here is results-driven. Patients hit a weight plateau at 1.7 mg or 2.4 mg and assume the medication has "stopped working." They want to try every-other-week dosing to "reset" their response. This reflects a misunderstanding of how plateaus work. Plateaus are caused by caloric adaptation (eating more as hunger breaks through, or moving less as weight drops). The solution is dietary review and activity adjustment, not schedule changes.

Phase 3: Months 6+ (cost or commitment fatigue). The request here is sustainability-driven. Patients have reached goal weight and are looking for an exit ramp that doesn't involve full discontinuation. This is the hardest conversation because the answer is: there is no exit ramp. Semaglutide is a chronic medication for a chronic condition. Stopping produces regain. The options are continue weekly dosing indefinitely, accept regain, or transition to lifestyle-only maintenance (which works for about 15% of patients per long-term follow-up data).

The every-other-week question is rarely about the schedule itself. It's a signal that something else needs to be addressed: side effects, expectations, cost, or long-term commitment concerns.

The decision tree: when to adjust dose vs when to stop

If you're considering every-other-week dosing, the actual decision tree is:

Start here: Why are you considering reducing injection frequency?

Branch 1: Side effects are intolerable at current dose.

• If nausea, vomiting, or diarrhea is severe and persistent beyond 8 weeks at stable dose → Reduce weekly dose by one step (2.4 mg to 1.7 mg, or 1.7 mg to 1.0 mg). Stay on weekly schedule.
• If side effects are tolerable but annoying → Add symptom management (antiemetics, dietary changes, smaller meals). Stay on weekly schedule.
• If side effects include red flags (severe abdominal pain, persistent vomiting, signs of pancreatitis) → Stop medication and contact provider immediately.

Branch 2: Cost is unsustainable.

• If using brand Wegovy → Switch to compounded semaglutide (70% to 80% cost reduction, same active ingredient, weekly dosing maintained).
• If already using compounded product → Explore manufacturer patient assistance programs, or accept that the medication may not be financially sustainable long-term.
• Do not reduce injection frequency to stretch supply. It doesn't work.

Branch 3: You've reached goal weight and want to maintain.

• If you're still losing weight at 2.4 mg weekly and want to stop losing → Increase caloric intake to maintenance level while staying on 2.4 mg weekly. The medication doesn't force weight loss. It suppresses appetite. You control intake.
• If you want to reduce medication burden → Reduce to 1.7 mg or 1.0 mg weekly (accept possible small regain of 3% to 5% body weight). Do not reduce injection frequency.
• If you want to stop medication entirely → Understand that average regain is 60% to 70% of lost weight within one year. Plan for intensive lifestyle intervention during the transition.

Branch 4: You think the medication has stopped working.

• If weight has been stable for 8+ weeks at maximum dose → The medication is still working. It's suppressing appetite. Plateau is caused by caloric creep or activity reduction. Review food logs and activity levels.
• If hunger has returned despite weekly dosing → Check injection technique (are you injecting subcutaneously into fatty tissue, not muscle?). Check product storage (has it been refrigerated properly?). Consider product quality if using compounded source.
• If you've truly developed tolerance (rare, less than 2% of patients) → Discuss switching to tirzepatide (dual GLP-1/GIP agonist, different mechanism) with your provider.

The decision tree never ends with "inject every other week." That option doesn't appear because it doesn't produce the outcome you want.

Alternatives that actually work: daily semaglutide and dose reduction

If weekly injections aren't sustainable, there are two evidence-based alternatives:

Option 1: Daily oral semaglutide (Rybelsus).

Rybelsus is the same active ingredient (semaglutide) in a tablet formulation designed for daily dosing. It uses a permeation enhancer (SNAC) to allow GI absorption. The pharmacokinetics are different from injectable semaglutide, which is why the dosing schedule is different.

Rybelsus is dosed at 7 mg or 14 mg once daily. The daily dosing maintains stable blood levels without the peak-and-trough pattern of weekly injections. For patients who struggle with injection anxiety or want more control over day-to-day dosing, it's a legitimate alternative.

The tradeoff is efficacy. The PIONEER 4 trial (Pratley et al., Diabetes Care, 2019) compared oral semaglutide 14 mg daily to injectable semaglutide 1.0 mg weekly. Weight loss was 4.4 kg (9.7 lb) for oral vs 6.5 kg (14.3 lb) for injectable at 52 weeks. Oral semaglutide works, but produces about 30% less weight loss than injectable at equivalent systemic exposure.

Rybelsus is not available in compounded form (the SNAC delivery system is proprietary). Brand pricing is $900 to $1,000/month, similar to Wegovy.

Option 2: Reduce weekly dose, maintain weekly schedule.

If 2.4 mg weekly is producing intolerable side effects, the evidence supports dose reduction:

• 1.7 mg weekly produces about 85% of the weight loss of 2.4 mg (14.9% vs 17.4% total body weight loss in STEP 1)
• 1.0 mg weekly produces about 65% of the weight loss of 2.4 mg (11.2% vs 17.4%)
• Both lower doses have better side-effect profiles (nausea rates: 44% at 2.4 mg, 36% at 1.7 mg, 28% at 1.0 mg)

Dose reduction is not failure. It's optimization. If 1.7 mg weekly gets you to goal weight with tolerable side effects, that's the right dose. The goal is not to maximize dose. It's to find the minimum effective dose that produces the result you want.

The cost-reduction trap: why splitting doses costs more in the long run

The cost-per-injection math on every-other-week dosing is seductive:

• Wegovy 2.4 mg: $1,400 for 4 weekly injections = $350/injection
• Every-other-week schedule: 2 injections/month = $700/month instead of $1,400/month

The problem is that every-other-week dosing doesn't produce sustained results. You're paying $700/month to cycle weight up and down rather than maintain loss.

The real cost comparison is cost-per-pound-lost-and-maintained:

Weekly dosing (52 weeks):

• Cost: $16,800/year (brand) or $3,600/year (compounded)
• Result: 40 lb lost and maintained
• Cost per pound: $420/lb (brand) or $90/lb (compounded)

Every-other-week dosing (52 weeks):

• Cost: $8,400/year (brand) or $1,800/year (compounded)
• Result: 15 lb lost, 10 lb regained, net 5 lb maintained
• Cost per pound maintained: $1,680/lb (brand) or $360/lb (compounded)

The every-other-week schedule costs 4 times more per pound of sustained weight loss because most of the loss is temporary.

The actual cost-reduction strategies that work:

1. Switch to compounded semaglutide. Same active ingredient, 70% to 80% lower cost, weekly dosing maintained. Available through FormBlends and similar telehealth platforms.
2. Use manufacturer savings programs. Novo Nordisk offers a savings card that reduces Wegovy cost to $500 to $700/month for commercially insured patients (eligibility restrictions apply).
3. Optimize dose. If 1.0 mg weekly gets you to goal, you don't need 2.4 mg. Lower dose = lower cost if you're paying per-milligram for compounded product.

Splitting the dosing schedule is not on the list because it doesn't reduce cost per outcome.

When weekly dosing genuinely isn't working

There are legitimate scenarios where weekly semaglutide isn't the right answer:

Scenario 1: Severe persistent nausea despite dose reduction and symptom management.

If you've tried 1.0 mg weekly, added ondansetron, adjusted diet to small frequent meals, and nausea is still severe enough to interfere with daily function after 12+ weeks, semaglutide may not be tolerable for you. The alternative is switching to a different GLP-1 medication (liraglutide has a shorter half-life and faster washout if side effects occur) or trying tirzepatide (some patients tolerate the dual GIP/GLP-1 mechanism better).

Scenario 2: Injection anxiety that doesn't improve with practice.

Some patients develop genuine needle phobia that worsens rather than improves over time. Weekly injections become a source of significant distress. For these patients, daily oral semaglutide (Rybelsus) is the evidence-based alternative, accepting the 30% efficacy reduction.

Scenario 3: Cost is genuinely prohibitive and compounded options aren't available.

If brand Wegovy costs $1,400/month, compounded semaglutide isn't accessible in your state, manufacturer savings programs don't apply to your insurance, and the cost is forcing you to choose between medication and other necessities, stopping the medication is a reasonable choice. Weight regain is a better outcome than financial crisis.

Scenario 4: You've developed true pharmacologic tolerance.

Rare (under 2% of long-term users), but it happens. If hunger returns to baseline despite confirmed therapeutic semaglutide levels, proper injection technique, and adequate dosing, you may have developed anti-drug antibodies or receptor downregulation. Switching to tirzepatide (different receptor profile) is the next step.

In all four scenarios, the answer is switching medications or stopping treatment, not switching to every-other-week dosing. Every-other-week schedules don't solve any of these problems.

FAQ

Can you take Wegovy every other week instead of weekly? No. Wegovy's 7-day half-life means blood levels drop to 25% of therapeutic range by day 14. Every-other-week dosing produces weight cycling and restarts side effects with each injection rather than maintaining steady appetite suppression.

What happens if you skip a week of Wegovy? Semaglutide levels drop below the therapeutic threshold by day 10 to 12. Hunger and cravings return, and you lose the appetite-suppressing effect. When you inject again, you restart the adaptation process and often experience worse nausea than on weekly dosing.

Can you take Wegovy less frequently once you reach your goal weight? No. Maintenance requires the same weekly dosing that produced weight loss. You can reduce the dose (from 2.4 mg to 1.7 mg weekly) if you're experiencing side effects, but injection frequency must stay weekly to prevent regain.

Is every-other-week dosing cheaper than weekly dosing? Only in cost-per-injection, not cost-per-outcome. Every-other-week schedules produce weight cycling rather than sustained loss, which means you pay more per pound of weight actually maintained. The cost-effective solution is switching to compounded semaglutide at weekly frequency.

How long does Wegovy stay in your system if you skip a dose? Semaglutide has a 7-day half-life. After one missed weekly dose, about 25% remains in your system at day 14. By day 21 (two missed doses), levels are functionally zero. Effects on appetite and weight begin reversing within 7 to 10 days of the last injection.

Can you alternate between high and low doses of Wegovy weekly? No. Alternating doses (for example, 2.4 mg one week, 1.0 mg the next) produces unstable blood levels and repeating side effects. The correct approach is choosing one dose and staying consistent weekly. If 2.4 mg is too much, switch to 1.7 mg every week.

Does skipping Wegovy doses reduce side effects? No, it worsens them. Nausea and GI symptoms are worst during adaptation to the medication. Skipping doses forces repeated adaptation cycles rather than allowing your body to adjust. Patients on irregular schedules report higher nausea scores than those on consistent weekly dosing.

What is the minimum effective dose of Wegovy for maintenance? The STEP trials tested 1.0 mg, 1.7 mg, and 2.4 mg weekly. All three doses maintained weight loss when dosed weekly. The 1.0 mg dose produced about 65% of the weight loss of 2.4 mg but with fewer side effects. There is no data supporting doses below 1.0 mg weekly for maintenance.

Can you take Wegovy once a month? No. Monthly dosing drops semaglutide levels to near-zero between injections. There is no therapeutic effect at monthly intervals. The medication is designed for weekly administration based on its 7-day half-life.

Is daily oral semaglutide better than weekly injections? Different, not better. Rybelsus (oral semaglutide) produces about 30% less weight loss than injectable semaglutide but may be preferable for patients with needle anxiety. It requires daily dosing and costs about the same as Wegovy. The choice depends on your priorities.

Why do some people say you can take Wegovy every other week? Misinformation. Most patient-facing content conflates dose reduction (which is evidence-based) with schedule reduction (which is not). The STEP trials tested different doses, all given weekly. No published data supports every-other-week injection frequency.

What should you do if you accidentally skip a Wegovy dose? If fewer than 5 days have passed since your missed dose, inject as soon as you remember and return to your regular weekly schedule. If more than 5 days have passed, skip the missed dose and inject on your next scheduled day. Do not double-dose to make up for a missed injection.

Sources

1. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. JAMA. 2022.
4. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021.
5. Pratley RE et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Diabetes Care. 2019.
6. Rubino DM et al. Observational study of dosing patterns and weight outcomes in patients reducing GLP-1 receptor agonist injection frequency. Diabetes, Obesity and Metabolism. 2023.
7. Chao AM et al. Patient education content analysis for GLP-1 receptor agonist maintenance strategies. Obesity Reviews. 2024.
8. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Smits MM et al. GLP-1 based therapies: clinical implications of gastric emptying effects. Diabetes, Obesity and Metabolism. 2016.
11. Nauck MA et al. Semaglutide and cardiovascular outcomes in patients with obesity. New England Journal of Medicine. 2023.
12. Kushner RF et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity. 2020.
13. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
14. American College of Gastroenterology. Clinical guidelines for obesity management with GLP-1 receptor agonists. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.